Guidance for industry: Diabetes mellitus—Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Accessed at www.fda.gov/cder/guidance/index.htm Accessed July, 2016.
2.
SwislockiAL, JialalI. Diabetes Management and cardiovascular risk: Are SGLT-2 inhibitors the safest?. Metab Syndr Relat Disord, 2016; 14:3–6.
3.
MarsoSP, DanielsGH, Brown-FrandsenK, et al.; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375:311–322.
DruckerDJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab, 2016; 24:15–30.
6.
JialalI, DhindsaS. Hypoglycemia and the predisposition to cardiovascular disease: Is the pro-inflammatory-pro-coagulant diathesis a plausible explanation?. Atherosclerosis, 2016;pii: S0021-9150(16)30246-5.
7.
PfefferMA, ClaggettB, DiazR, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med, 2015; 373:2247–2257.
8.
TahraniAA, BarnettAH, BaileyCJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nature Rev Endocrinol, 2016. [Epbub ahead of print]; DOI: 10.1038/nrendo.2016.86.
9.
MeierJJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol, 2012; 8:728–742.
10.
MontoriVM, Rodriguez-GutierrezR. The triumph of innovation and the hard work of caring for patients with diabetes. Ann Intern Med, 2016; 164:127–128.
11.
McCarthyM. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner. BMJ, 2015; 351:h6702.
12.
MonamiM, DicembriniI, NardiniC, et al.Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab, 2014; 16:38–47.
13.
ZaccardiF, HtikeZZ, WebbDR, et al.Benefits and harms of once-weekly glucagon-like peptide-1 receptor agonist treatments: A systematic review and network meta-analysis. Ann Intern Med, 2016; 164:102–113.
14.
ScheenAJ. [Lixisenatide (Lyxumia), a new agonist of glucagon-like peptide-1 receptors with a predominant postprandial action]. Rev Med Liege, 2014; 69:102–109.
15.
FiorentinoTV, SestiG. Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors. Endocrine, 2015; 53:373–380.
